DELPHAI, AI Agent for Predicting Drug Response and Resistance
Peng, T.; Wu, H.; LIU, H.-K.; Zhang, X.
Show abstract
Patient-derived organoids preserve critical tumor features and drug sensitivity patterns that mirror patient clinical responses, enabling single-cell RNA sequencing analysis of drug responses. Analyzing these perturbation data presents significant computational challenges in predicting cellular responses while maintaining biological interpretability. We developed DELPHAI (Deep ExplainabLe Predictive Human-organoid based AI), an AI agent that integrates single-cell perturbation prediction with mechanistic analysis using large language models. We designed a comprehensive benchmarking framework evaluating methods in both computational embedding and reconstructed gene expression spaces. Applied to glioblastoma organoids treated with temozolomide, optimal transport combined with principal component analysis outperformed baseline methods in capturing population dynamics. DELPHAI correctly identified DNA alkylation as the mechanism of action without prior drug knowledge and recommended combination therapies aligning with clinical trials. These results demonstrate DELPHAPs ability to translate single-cell perturbation data into actionable therapeutic insights, representing a significant advance toward Al-driven precision medicine in cancer treatment.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones 95%
- Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics 95%
- Community assessment of cancer drug combination screens identifies strategies for synergy prediction 94%
Similar papers in this journal
- Defining subpopulations of differential drug response to reveal novel target populations 96%
- Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors 95%
- Merging metabolic modeling and imaging for screening therapeutic targets in colorectal cancer 94%
Similar papers in this journal
Similar papers in this journal
- Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines 95%
- Interpretable Deep Learning for Improving Cancer Patient Survival Based on Personal Transcriptomes 95%
- Intracellular Optical Doppler Phenotypes of Chemosensitivity in Human Epithelial Ovarian Cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.